Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | TYK2 | P29597 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.31 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31489146 | 0.94 | JAK2 (0.33) | JAK2JAK1TYK2JAK3PIK3CD | |
| SCHEMBL31489684 | 0.91 | PIK3CD (0.34) | JAK2JAK1TYK2JAK3PIK3CD | |
| SCHEMBL31489626 | 0.86 | JAK2 (0.34) | JAK2JAK1TYK2JAK3PIK3CD | |
| SCHEMBL31489446 | 0.86 | CYP17A1 (0.32) | JAK2JAK1TYK2JAK3CYP17A1 | |
| SCHEMBL31489341 | 0.84 | JAK2 (0.33) | JAK2JAK1TYK2JAK3CYP17A1 | |
| SCHEMBL31489655 | 0.83 | PIK3CD (0.32) | PIK3CDPIK3CAPIK3CGCYP17A1 | |
| SCHEMBL31489532 | 0.81 | JAK2 (0.34) | JAK2JAK1TYK2JAK3PIK3CD | |
| SCHEMBL31489378 | 0.80 | PIK3CD (0.35) | PIK3CDPIK3CAPIK3CG | |
| SCHEMBL31489294 | 0.78 | CYP17A1 (0.34) | JAK2JAK1TYK2JAK3PIK3CD | |
| SCHEMBL31489517 | 0.78 | PIK3CD (0.34) | PIK3CDPIK3CAPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025072395-A1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-04-03 | — | — | WO | disclosed |